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Todd R. Ackerman Jr 
THE EFFECTS OF VERTEPORFIN ON 
NON-SMALL CELL LUNG CANCER 
 
 Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers and is the 
leading cause of cancer death in the Unites States. Better treatments must be devised in 
order to improve the prognosis of this disease. Verteporfin, an FDA approved drug, has 
recently been reported to downregulate a potential core pathway of NSCLC, the Hippo 
pathway. The pathway consists of a kinase cascade to control the transcriptional 
coactivators YAP and TAZ. When these transcriptional coactivators lack phosphorylation 
of key residues, they are able to translocate into the nucleus and bind to the TEAD 
member of transcription factors. This augments transcription for genes responsible for 
proliferation, survival, and stem maintenance. In this study, we report that verteporfin 
limits proliferation and survival of NSCLC and may potentially be a viable treatment 
option. Inhibition of cell survival dose-dependently correlated with inhibition of YAP-
TEAD transcription target CTGF. We also report the covalent homo-oligomerization of 
p62, a prominent protein involved with autophagy, with the introduction of verteporfin 
into NSCLC cells.  
 
       Lawrence A. Quilliam, Ph.D., Chair 
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INTRODUCTION 
 
Non-small cell lung cancer (NSCLC), accounts for 85-90% of lung cancers. 
According to the American Cancer Society “Lung cancer accounts for about 27% of all 
cancer deaths and is by far the leading cause of cancer death among both men and 
women. Each year, more people die of lung cancer than of colon, breast, and prostate 
cancers combined.”(1) Finding a new way to treat this cancer and improve prognosis is of 
great need. A signaling pathway that may prove effective in targeted drug therapy for 
NSCLC is the Hippo pathway. The Hippo pathway consist of a series of kinases that 
regulate the transcriptional co-activators Yes-associated protein (YAP) and WW domain-
containing transcription regulator protein 1/transcriptional coactivator with PDZ binding 
motif (TAZ). These transcriptional co-activators can go on to activate members of the  
TEAD transcription factor family, and potentially other transcription factors, to control 
proliferation, survival, and stem cell maintenance (2-4).Targeting this pathway may 
prove to be very promising in the treatment of lung cancer.  
Visudyne (Verteporfin), an FDA approved drug for the treatment of macular 
degeneration, has been shown to have a negative effect on TEAD downstream 
transcription. The current understanding of how verteporfin accomplishes this is through 
preventing the YAP-TEAD complex from forming [5]. Hence, treatment with verteporfin 
could effectively treat cancers with aberrant Hippo activity. NSCLC cell growth has been 
shown to be inhibited by overexpressing MST1, preventing YAP from acting as a 
transcriptional coactivator (5). From this it can be hypothesized that verteporfin would be 
effective in the treatment of lung cancer.  
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The Hippo Pathway 
The Hippo pathway is a fairly recently identified pathway, with the orthologs 
being first discovered in 2002 in Drosophila melanogaster. The pathway was found to be 
highly conserved in mammals and to be a major controller of organ size, which was 
unprecedented in other pathways (4). The elicited response to mutation in any one of the 
upstream kinases in the Hippo pathway generates an overgrowth of the targeted organ. 
These mutations diminish the kinases function to phosphorylate, ultimately inactivating 
the Hippo pathway. This inactivated form allow for increased proliferation and cell 
growth akin to that of a tumor (2).  
The mammalian Hippo pathway begins with the protein complex of MST1, 
MST2, and SAV1. When the pathway is active, the phosphorylated MST1/2 complex 
phosphorylates the complex of large tumor suppressors 1 and 2 (LATS1/2) and MOB1. 
This in turn activates the LATS1/2 kinases to phosphorylate YAP/TAZ. This event keeps 
YAP and TAZ sequestered in the cytosol, preventing them from acting upon transcription 
factors in the nucleus. Depending on the phosphorylation site on YAP and TAZ, it will 
either be retained in the cytoplasm or marked for degradation. There are five known sites 
for LATS1/2 to phosphorylate YAP, 4 of these being conserved in TAZ.  A 
phosphorylation event of YAP on serine 127 creates a 14-3-3 binding site, which will 
keep it retained in the cytoplasm. Subsequent Phosphorylation of serine 381 triggers 
ubiquitination and proteasomal degradation of YAP (3,6). However, if the pathway is 
never initiated, YAP and TAZ will be in their active unphosphorylated form and be able 
to cross the nuclear membrane to act as transcriptional co-activators. 
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Figure 1. Depiction of the core cascade of the Hippo pathway in its active and 
inactive states. In active Hippo signaling, the phosphorylated MST1/2-SAV1 complex 
go on to phosphorylate LATS1/2, which in turn phosphorylate YAP/TAZ. This event 
keeps YAP from translocating into the nucleus and act as a transcriptional co-activator of 
TEAD1-4. In inactive Hippo signaling, the phosphorylation cascade never occurs, 
allowing YAP/TAZ to act on TEAD1-4 to modulate transcription. 
 
 
Upstream signaling of the Hippo pathway is poorly understood. The core kinase 
cascade of the Hippo pathway is controlled by a multitude of factors that all go into 
sensing the physical state of the cell. A very prominent feature of the Hippo pathway is 
its interconnection with other cellular pathways (7). This interconnectedness allows the 
Hippo pathway to sense and respond to energy levels, cellular contact, growth factors, 
and polarity of the cell. In tumor conditions, these interconnections may funnel some of 
the classical phenotypes seen in tumors through the Hippo pathway; making it a great 
potential therapeutic target. 
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Verteporfin 
Verteporfin, trademarked as Visudyne, is currently used in the photodynamic 
treatment of age related macular degeneration. It is composed of two regioisomers (same 
chemical formula, but a functional group changes position on the parent molecule), which 
are listed below. The drug is activated at a 690nm wavelength, at which point singlet 
oxygens are produced while in the presence of oxygen (8). After its FDA approval, it was 
also found to suppress the oncogenic activity of YAP without the need for light activation 
(9). To demonstrate whether verteporfin binds to YAP or TEAD, Liu-Chittenden et al 
mixed verteporfin with purfied versions of the proteins. The author found that verteporfin 
coeluted with YAP, signifying verteporfins binding partner is in fact YAP.   
  
 
 
Figure 2. The two regioisomers of verteporfin. 
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 Verteporfin is known to produce singlet oxygens with exposure to light, but these 
reactive species appear to be produced at modest levels even without light exposure 
(10,11). Singlet oxygen is a short-lived electrophilic molecule that reacts rapidly with 
unsaturated carbons, neutral nucleophiles and anions (12,13).  Verteporfins basal 
production of singlet oxygens causes damage to proteins near the site of where it was 
formed. Consequently, some proteins may become non-functional or aggregate protein 
crosslinks may arise. This is problematic for potential therapeutic value, as proteotoxicity 
may be unavoidable. On the other hand, this could be a very useful secondary function of 
verteporfin. Some studies have reported normal cells are able to clear out the proteotoxic 
effects of verteporfin while tumor cells cannot (11,14). If this is the case, it adds more 
credence to verteporfin being an effective cancer treatment.  
 Another interesting phenomenon cells exhibit when exposed to verteporfin is the 
lack of autophagy (10). This phenotypic change can be attributed to the polymerization of 
p62 with itself. The protein p62, also known as sequestosome 1 (SQSTM1), is a 
multifunctional adaptor protein that recognizes and loads ubiquinated cargo into an 
autophagosome (10,15). The singlet oxygens produced basally by verteporfin cause this 
multimerization of p62. Which is also a downward slope, as more p62 polymerize, less 
autophagic degradation occurs, allowing more damaged proteins to build up. This may 
also be a major proponent of cell death with verteporfin treatment.  
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METHODS 
 
Cell Passaging 
Stock plates of cell lines were passaged every 3 days for the H460 cells and 3 to 4 
days for H23 cells in RPMI 1640 medium supplemented with 10% fetal bovine serum 
and penicillin/streptomycin.  Medium was aspirated off the stock plates and replaced with 
10 mLs of dPBS. dPBS was then aspirated and replaced by 1 mL of trypsin/EDTA 
solution, followed by being placed into a cell culture incubator for 5 minutes. Afterwards, 
9 mLs of media was dispensed onto the cell suspension to inactivate the trypsin. The 
suspension was then agitated by gently pipetting up and down several times to ensure all 
cells are detached from the plate and each other. Cells were then quantitated by pipetting 
10 uLs onto both sides of a hemocytometer and counting five squares on each side. Stock 
plates were set at 200,000 – 300,000 cells per 10 cm dish.  
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Clonogenic Assay 
To assay for survival and proliferation, clonogenic assays were conducted. Cells 
were diluted to 167 cells per mL of media. Three mLs of the diluted cell suspension was 
dispensed onto a 60 mm plate for approximately 500 cells per plate. Plates were then 
incubated in a cell culture incubator for 24 hours. Media was aspirated and replaced with 
fresh media infused with verteporfin concentrations listed below. Cells were left to 
incubate for 72 hours. The media was then aspirated off and the dish was washed twice 
with 3 mLs of dPBS. Following aspiration of the dPBS, fresh media was placed into the 
dish and placed back into the cell culture incubator. At this point the cells were left to 
recover from the exposure to verteporfin. The recovery process takes 7-9 days. During 
this period, the media was changed out by day 4. Once the colonies on the control plate 
were visibly noticeable, the plates were processed for staining. Media was aspirated and 
plates were washed with 4 mLs of dPBS. After aspirating the wash, 3 mLs of 10% acetic 
acid / 10% methanol was pipetted onto the plate as a fixative. The plates were then 
incubated for 20 minutes followed by removing the fixative. Crystal violet was then used 
to stain the cells for visualization and potential colony counting. One mL of crystal violet 
was pipetted onto each plate and let sit for 20 minutes. The residual crystal violet is then 
aspirated off of the plates and washed under a low-pressure stream of water. The wash 
was performed 4-5 times or until all of the residual crystal violet is washed away. The 
stained colonies are then visualized and interpreted for changes in survival and 
proliferative capacity.  
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MTT Assay 
Measurements of cell viability and proliferation were also acquired utilizing MTT 
assays. This assay assesses cells metabolic activity via oxidoreductase enzymes reducing 
the tetrazolium dye MTT to formazan.  Cells were set on a 96 well plate at 2000 cells per 
well. The plates were incubated for 24 hours at 37° C. Media was then aspirated and 
replaced with media infused with drug concentration of choice, in triplicates. Plates were 
then incubated for ~72 hours in the cell culture incubator. 10 uLs of MTT Reagent was 
added to each well and incubated for ~4 hours. Media was aspirated and 100 microliters 
of alcohol/detergent reagent was added to each well to dissolve the precipitate. After 3 
hours of incubation in the dark, the plate was then quantified on a spectrophotometer, 
recording at an absorbance of 570 nm.  
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Matrigel Assay 
Matrigel assays were conducted to view cell morphology and phenotype changes 
with the addition of verteporfin in three-dimensional culture. Matrigel was thawed to 4° 
C, 200 uLs was pipetted onto a 40 mm dish and spread evenly across the center of the  
plate with a pipette tip. Plates were then incubated in a cell culture incubator for 20 
minutes to allow the Matrigel to set. During this time cells were trypsinized and counted. 
200,000 cells were dispensed on top of the Matrigel and let set for 24 hours. Media was 
aspirated and replaced with verteporfin infused media. At periodic intervals, microscopic 
images were collected of each set of plates at 4X or 10X magnification to discern any 
phenotypic changes with the cells.  
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ALDEFLUOR Assay 
To assess the percentage of stem like cells in culture, an ALDEFLUOR assay was 
ran on H460 cells and H460 spheroids. The ALDEFLUOR measures aldehyde 
dehydrogenase (ALDH) activity within the cell by generating a fluorescent product, 
effectively enabling measurement via a flow cytometer. ALDH expressing cells are 
associated with a stem like nature. For the H460 cells, the plates were trypsized for 5 
minutes and inactivated with media. After quantitation with a hemocytometer, 200,000 
cells were aliquoted from the cell suspension and placed into a 15 milliliter conical tube 
and centrifuged at 800 RPM for 5 minutes. Supernatant was aspirated away without 
disturbing the cell pellet. The cells were washed with 10 mL of dPBS and centrifuged at 
800 RPM for 5 minutes. The supernatant was then aspirated off and the pellet was 
resuspended into 1 mL of the ALDEFLUOR assay buffer. Two 4 mL test tubes were 
labeled as experimental and control. The 1 mL of cell suspension resuspended in the 
assay buffer was then transferred into the experimental tube. Five uL of the DEAB 
(ALDH inhibitor) solution was pipetted into the control tube. Five uL of the activated 
ALDEFLUOR substrate was pipetted into the test tube and immediately afterwards 500 
uL from the test tube was transferred into the control tube. Samples were incubated for 40 
minutes at 37° C. The tubes were then centrifuged at 250 x g for 5 minutes and the 
supernatant was aspirateded. Lastly, 500 uL of ALDEFLUOR assay buffer was added to 
both tubes and stored on ice. The samples were ran on a cytometer as soon as possible, as 
the fluorescence drops in a time dependent manner. 
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Folate-FITC Assay 
To quantitate the amount of available folate receptors on the H460 cells FACS 
analysis was done using folate conjugated to FITC. H460 cells were grown in folate-free 
media for 2 weeks prior to testing. This was done to permit folate receptors to reach a 
level more akin to what it would be in vivo. Controls for this experiment were acquired 
by using KB cells, which are known to have high cell surface folate receptor levels. To 
avoid degradation of any surface receptors, cells were trypsinized for no longer than 5 
minutes. Trypsin was then inactivated using folate-free media and cells counted. After 
quantitation, 100,000 cells were aliquoted out of suspension and centrifuged at 800 RPM 
for 5 minutes. Supernatant was aspirated and 500 uL of minus folate and minus serum 
media was dispensed into the positive control and the experimental tube. For the negative 
control, dispense 500 uL of plus folate minus serum media, which will compete with the 
folate-FITC conjugate. Afterwards, 50 uL of the folate-FITC conjugate was pipetted into 
each suspension and incubated for 30 minutes. Suspension was then washed twice with 
cold dPBS and centrifuged at 800 RPM for 5 minutes. Supernatant was aspirated and 
replaced with 500 uL of dPBS. Samples are ready to be ran on a cytometer at this point.  
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SDS PAGE Western Blotting 
Cells were plated on 40 mm dishes at 100,000 per plate and let set for ~24 hours. 
Desired verteporfin and reducing agent concentrations were made and added to dishes. 
After 24 hours, media was aspirated and washed with ice cold PBS. Cells were lysed in 
200-300 uLs of phospho-tyrosine lysis buffer (50 mM Hepes, pH 8.0, 50 mM NaCl, 2 
mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM Na3VO4,  10 mM NaF, 10 mM 
NaH2PO4, 100 KIU/ml aprotinin and 1 mM PMSF). Plates were scraped and re-aliquoted 
into sterile micro-centrifuge tubes. Lysates were centrifuged at 800 G for 10 minutes at 
4° C. Supernatant was added to a fresh micro-centrifuge tube with the pellet being 
discarded. The Bradford protein assay was conducted to acquire protein concentration per 
lysate. Using the given concentrations, thirty micrograms of protein was pipetted from 
lysates and added to ten microliters of 4x loading buffer. Samples were placed into a 
water bath set at 90° C for five minutes to denature sample proteins and coat them with 
sodium dodecyl sulfate. After denaturation, samples were placed in a micro-centrifuge to 
pull down any water that was evaporating from the boiling process. The entirety of the 
samples were then pipetted into individual wells in an 8 % poly-acrylamide gel. BD 
bioscience all-blue protein ladders were used to delineate protein size. Gels were ran with 
ice cold running buffer at 90-100 milliamps for 90 minutes. Once the run was completed, 
the transfer apparatus was prepared. PVDF membranes were activated in 100% methanol 
and placed on top of two filter papers soaked in transfer buffer. The gel was taken out of 
the running apparatus and placed on top of the membrane, assuring no formation of air 
bubbles. Another filter paper soaked with transfer buffer was placed over the gel. A roller 
was used to force any air bubbles that may have formed out of the compilation. The 
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clamp was closed and submerged into the transfer apparatus. A constant voltage was 
used, set at 100V, to transfer the proteins set on the gel to the PVDF membrane. The 
transfer was ran for one hour with an ice pack placed inside. After completion a Ponceau 
Stain was conducted to confirm  proper transfer of proteins. At this point, the membrane 
was blocked for 24 hours in 5% skim milk at 4° C. After blocking, the membrane was 
washed twice in tris-buffered saline with 1% Tween-20 added (TBST). Membrane was 
split in half, cut underneath the 50 kilodalton band on the protein ladder.  
PRIMARY ANTIBODY Antibody dilution inTBST (uL) 
P62 1/5000 
YAP 1/2000 
LC3 1/3000 
β-Actin 1/10000 
GAPDH 1/10000 
Table 1. List of antibodies and dilutions. 
Primary antibodies were diluted, as listed above, and added to the respective 
membrane for one hour. Three washes with TBST for 5 minutes were conducted to wash 
off any nonspecific binding. After washing, the secondary antibody was added to both 
membranes for thirty minutes (Anti-Mouse HRP 1:30000 TBST). Another series of 
washes was conducted, a total of five for five minutes per wash with TBST. Using 
enhanced chemiluminescence, the membranes were developed in a dark room using 
autoradiography. 
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Reverse Transcriptase PCR 
Cells were set at 250,000/10 cm dish dish and placed into a cell culture incubator 
for 24 hours. Media was aspirated and replaced with fresh media infused with verteporfin 
concentration of choice for 24 hours in a cell culture incubator. After the 24 hour 
exposure, media was aspirated off, and the dish was washed with ice cold PBS and 
aspirated off. One milliliter of Tri-Reagent was placed into each dish. Using a sterile 
scraper, the entire area of the dish was scraped and the Tri-Reagent was pooled into an 
area on the dish. The entirety of the solution was then pipetted into a sterile DNAase and 
RNAase free micro-centrifuge tube. At this point, tubes were either frozen at -80° C 
being processed at a later time or RNA was immediately isolated out of the solution. 
When isolating RNA, 200 uL of chloroform was pipetted into each micro-centrifuge tube 
and inverted for at least 15 seconds. After 5 minutes, at room temperature, tubes were 
centrifuged at 12,000 G for 15 minutes at 4° C. The tubes were then carefully placed into 
a clean rack and the clear supernatant was pipetted into a fresh DNAase and RNAase free 
micro-centrifuge tube. To precipitate out the RNA, 500 uL of isopropanol was then 
added. After 5 minutes, the tubes were centrifuged at 12,000 G for 10 minutes at 4° C. 
The supernatant in the tubes is discarded and then washed with one milliliter of 70% 
ethanol. The tubes were centrifuged at 12,000 G for 5 minutes. Supernatant is discarded 
without disturbing the pellet. The tubes are then incubated in a water bath at 37° C until 
the remainder of the ethanol has evaporated from the tubes. The RNA isolated in the 
pellet was then resuspended in 15 microliters of RNAse and DNAse free water. The tubes 
were then incubated at 50° C for 5 minutes to fully dissolve the RNA into solution. The 
concentration of RNA was then quantitated using a Nanodrop spectrophotometer. At this 
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point samples were standardized for reverse transcription, aliquoting 5 ug of RNA into 
PCR grade RNAse and DNAse free micro centrifuge tubes. Samples were then QS to 18 
microliters. In a separate container, random hexamers and dNTPs were mixed; using 4 
microliters of random hexamers per sample and 2 microliters of 10 mM dNTP per 
sample. Six microliters of the random hexamer and dNTP solution was dispensed into 
each sample for a total of 24 uL per tube. To facilitate annealing, micro centrifuge tubes 
were placed into a 60 degree water bath for 5 minutes. During this incubation the reverse 
transcriptase master mix was prepared. The master mix was comprised of 9 uL of 
nuclease free water, 1 uL of RNASE OUT, 4 uL of 10x reverse transcriptase buffer, and 
2 uL of MuLV reverse transcriptase. After the 5 minute incubation, the samples were 
taken out of the water bath and wiped dry with a Kim wipe. Afterwards, 16 uL of the 
reverse transcriptase master mix was dispensed into each sample tube. The samples were 
then incubated at 50° C for 50 minutes, and then 70° C for 5 minutes to denature the RT 
enzyme. The cDNA product was measured on the Nanodrop on the single strand DNA 
setting to acquire approximate cDNA values. At this point samples were standardized so 
that each contained the same amount of cDNA, assuring that enough diluent is used to 
perform the reactions desired. The master mix was assembled next; which consisted of 3 
ul of nuclease free water, 1 ul of both the forward and reverse primers, and 10 ul of 2x 
syBR green mix. With the mix completed, 15 ul was pipetted into a 96 well  PCR grade 
plate followed by 5 ul of the diluted cDNA sample. The plate was centrifuged and placed 
onto an Eppendorf Mastercycler to begin and measure the reactions.  
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RESULTS 
 
Preface 
 
 The basis for this work is that verteporfin has been shown to block aberrant YAP 
activity, and since NSCLC has been shown to be correlated with abnormal YAP activity 
(5,16-18), it can be hypothesized that proliferation and survival may decrease 
substantially by treatment with verteporfin. Beyond proliferation and survival, the change 
in gene expression brought on by verteporfin may sensitize stem-like populations by the 
change in gene expression. If true, verteporfin would be a great candidate for synergistic 
drug therapies as the stem cell populations of tumors are more resistant to traditional 
treatments. Another facet of verteporfin treatment that will be touched on is the 
oligomerization of p62 and the disruption of autophagy. Disrupting autophagy would 
have detrimental effects on tumor cells. This would put stressors on the cells that could 
lead to apoptosis or impaired function. All of these qualities may make verteporfin a very 
powerful tool in the fight against NSCLC. 
 The only problem that can be gleaned at this point is that there are no specific 
delivery systems to the cancer cells. In cell culture this is not an issue, but at the scale of 
an organism treatment may be difficult. A method that was looked into to aid in 
specificity was the conjugation of folate onto verteporfin. Tumor cells typically have 
upregulated folate receptors, as they are highly proliferative. This can be used to deliver 
verteporfin more specifically to them. This will be touched on in the last section of the 
results. 
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 To start off, proliferation and survival are looked at in H460 cells and H23 
NSCLC cells with the treatment of verteporfin. 
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Verteporfin Reduces Proliferation and Survival of NSCLC Cells 
To assess how treatment with verteporfin would affect NSCLC cell viability, an 
MTT assay was conducted. Several pilot experiments performed to ascertain how long 
the drug should be left on to have noticeable effects. The exposure time varied from 72 
hours, 96 hours, to 120 hours for these pilot experiments.  The difference in effectiveness 
was negligible, therefore 72 hours was chosen as the exposure time for the subsequent 
experiments.  
  
 
 
 
 
 
Figure 3. Verteporfin dose-dependently inhibits NCI-H460 cell viability. Viability is 
standardized to the control plate. cells were incubated with the indicated concentrations 
of verteporfin or DMSO solvent alone (all points were adjusted to 0.1% DMSO) for 72 
hours prior to performing the MTT assay. Data points were collected in triplicates. The 
IC50 is approximately 2.75 uM. 
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Results from the MTT assay show that a negative correlation between the 
concentration of verteporfin and NSCLC cell survival exists. To further reinforce that 
viability is decreasing as well as to get a more accurate IC50, a series of clonogenic 
survival assays were conducted. Approximately 500 cells were seeded onto 60 mm dishes 
a day before their exposure to verteporfin. Initial experiments established a narrower 
effective concentration of verteporfin than in the MTT assay. Therefore doses between 
100 and 500 nM were selected for subsequent survival assays. Dishes exposed to 
verteporfin are shown below in figure 2 for both the H460 and H23 cell line for three 
days. 
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B 
          H23 Cells 
 
 
 
Figure 4-A. Verteporfin reduces survival and proliferation in H460 NSCLC cells. 
Cells were exposed to DMSO solvent or verteporfin in a dose dependent manner for 72 
hours. After exposure, cells were washed and allowed to recover for 7-9 days. Cells were 
then fixed and stained with crystal violet for colony visualization. The IC50 for H460 
cells is approxiamately 0.2 uM of verteporfin.  
Figure 4-B. Verteporfin reduces survival and proliferation in H23 NSCLC cells. The 
IC50 in the H23 cells is 0.1 uM of verteporfin. Fewer colonies demonstrates that survival 
is decreasing. Smaller collonies is indicative of decreased proliferation. Higher 
concentrations that were used (resulting in complete loss of colony survival) are not 
shown. 
 
 
Surprisingly the IC50 was considerably lower in the clonogenic assay than it was 
in the MTT assay. This unexpected result yields some insight into how verteporfin may 
be reducing viability. There are several plausible mechanisms of actions for this result.  
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Cells are much more dispersed and in less dense colony formations in the clonogenic 
assay compared to the MTT assay. This would make the cells initially more dependent on 
Hippo signaling, since the cells had their junctions severed during the trypsinizing 
process and weren’t able to cluster back together. In the MTT assay the surface area is 
greatly reduced, allowing the NSCLC cells to cluster and perhaps be less dependent on 
the Hippo pathway. Increased density may be one reason why verteporfin is much more 
effective in the clonogenic assay as cells that are more dependent on the Hippo pathway 
may be more sensitive to verteporfin treatment. Another mechanism may just be a matter 
of time. In the clonogenic assay, after 3 days of exposure to verteporfin the media is 
aspirated, the plate is washed and replaced with fresh media; the cells are left to recover 
for several days at this point. This recovery period may facilitate the cells transition to an 
apoptotic state (significant cell death observed at the higher drug doses was not typically 
observed until after the cells had been in culture for 4-5 days). The last mechanism that 
was thought of is the potential for verteporfin to remain in the cytosol of the NSCLC cells 
after the plates were washed. Since verteporfin is hydrophobic,  it should flux in and out 
of a cell with relative ease. However, if for some reason it gets sequestered in the cytosol 
the recovery period may just be elongating exposure time. 
  With these two assays it can be said with a degree of certainty that verteporfin 
does indeed reduce the proliferative capacity as well as the surviability of NSCLC cells. 
The next step was to figure out how this might be accomplished.  
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Blocking the YAP-TEAD Interaction 
 
 The basis for verteporfin to be effective in reducing the viability of NSCLC was 
believed to be its blocking of YAP from binding to the TEAD family of transcription 
factors. To confirm that verteporfin is attenuating YAP activity in NSCLC cells, a series 
of RT-PCR assays were performed.  The gene CTGF was chosen to measure the efficacy 
of verteporfin to downregulate TEAD responsive genes, as CTGF is a prominent gene 
associated with YAP-TEAD activity and the most frequently monitored (19,20).   
 
 
 
 
 
 
Figure 5. CTGF expression is markedly reduced with the addition of verteporfin to 
media. H460 NSCLC cells were exposed to verteporfin for 24 hours at the concentrations 
above. Calculations were done using the comparative Ct method.  This figure was 
generated by a member of the Quilliam lab. 
 
 As expected, verteporfin decreases the expression of CTGF mRNA in a dose 
dependent manner. The IC50 was just under 200 nM and by 300 nM CTGF expression is 
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nearly a quarter what the control plate expressed, this shows how potent verteporfin is in 
inhibiting downstream TEAD transcription. This is a massive decrease that could 
potentially be extended to say that genes associated with TEADS are decreased perhaps 
to the same extent; phenotypically this means proliferation, survival, and a stem like 
nature should decrease as well. To confirm the above statement, other downstream TEAD 
genes would have to be monitored with verteporfin treatment. The results of the PCR 
correlate nearly perfectly with the dose response curve for the clonogenic assay. Which 
suggests that the mechanism of death for these cells may be through the Hippo pathway.   
 A contending hypothesis against the above role of verteporfin acting through 
inhibition of YAP-TEAD signaling was described shortly after my project began; 
verteporfin was shown to promote the oligomerization of p62, which blocks autophagy 
and may lead to cytotoxic apoptosis. The next section of the results will touch on this 
aspect of NSCLC cell response to verteporfin treatment. 
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Low Concentrations of Verteporfin Covalently Homo-Oligomerize p62  
 
 
 Donohue et al showed that verteporfin covalently homo-oligomerizes p62 and 
inhibits autophagy at 10 uM without light activation (10).  However, they do not show 
that that this crosslinking happens with the low concentrations used in the figures 4 and 5 
herein. An earlier study by this group also suggested that verteporfin impacted 
autophagy, but again, the doses of drug used were quite high compared to the nM levels 
used in figures 4 and 5. Initially, it was assumed that these oligomeric p62 constructs 
would not with the low concentrations of verteporfin being used in my studies. However, 
results proved these assumptions wrong. Numerous western blots were conducted, 
probing for p62, at different time points and concentrations demonstrating this finding. In 
subsequent experiments, antioxidants were used to try and prevent p62 oligomers from 
forming. Preventing p62 from oligomerizing would help establish if verteporfin is acting 
through the Hippo pathway or by other means. The antioxidants used were glutathione, α-
tocopherol, n-acetyl cysteine, and histidine. Histidine was shown to be the most effective 
at preventing p62 oligomers from forming and was used hereafter as a singlet oxygen 
squelcher. 
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Figure 6-A. Dose-dependent induction of H460 cell p62 oligomerization by 
verteporfin under low light conditions. Cells were exposed to indicated levels of 
verteporfin for 24 hours. Size markers are indicated in kDA 
Figure 6-B. Impact of histidine on verteporfin-induced p62 oligomerization. Cells 
were exposed to compounds for 12 hours. Histidine was shown to prevent p62 
oligomerization at 50 mM. 
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 As shown above in figure 4-A, verteporfin causes high molecular weight p62 
bands to appear as the dosage increases. This was expected, but not for the 100-200 nM 
range. Also, the exposure time is one-third that of the MTT and clonogenic assays. This 
is problematic for the initial hypothesis, as this puts a hole into the prior thinking. 
However, it is important to note that the samples used in figure 4-A were exposed to light 
during the processing of the samples, which may have had an effect on oligomerization. 
To discern whether oligomerization can be prevented or reduced, histidine was used as a 
singlet oxygen squelcher. As shown in figure 6-B, 50 mM of histidine blocks the 
oligomerization of p62 for 1 and 3 uM of verteporfin exposed to the cells for 12 hours. 
The MTT, clonogenic, and RT-PCR need to be redone using histidine in conjunction with 
verteporfin, to test if the previous results are attributed to the blocking TEAD 
downstream genes or cytotoxicity. Due to some unfortunate circumstances (several stock 
preparations of verteporfin lost effectiveness), it has been problematic to follow through 
with these experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
Folate-Verteporfin Conjugate 
 
 The conjugation of folate to verteporfin could potentially make it more specific 
for proliferating cells. Previous studies have shown the efficacy of conjugating folate to 
molecules to enhance delivery (21). This would be a major benefit in making verteporfin 
into a viable systemic treatment option. Another added benefit of folate conjugation 
might be increased solubility, which would further improve drug delivery in vivo. To test 
this, a preliminary study was conducted to quantify the level of folate receptors present 
on the NSCLC cell line H460. Quantifying the number of folate receptors is key, as 
they’re anticipated to be the major conduit of the conjugate into the cells. Once inside the 
cell, the folate should be cleaved off, which leaves verteporfin’s activities unchanged. 
However, if there are not enough folate receptors present, then the driving force will be 
diminished. NSCLC is known to have high levels of folate receptors (22), but conditions 
may change in cell culture. Cells have been passaged and grown in RPMI, which has a 
very high level of folate which would promote endocytosis and down-regulation of 
recpetors. Before testing the amount of folate receptors, the cells were passaged in folate 
free media for two weeks. This was done in hopes of restoring the folate receptors back 
to in vivo conditions.  
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Figure 7.   H460 cell line has a relatively low level of folate receptors. 
This experiment shows the relative amount of folate receptors present on the cell 
membrane. The first two plots are control runs with KB cells, which are known to be 
highly positive for folate receptors. This facilitates a negative and a positive control, with 
and without folate competition, respectively. The third chart depicts the relative amount 
of folate receptors on the H460 cell line after being cultured in the absence of folate for 
~10 days.  
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 The data from the folate uptake assay shows that there are very few folate 
receptors on the surface of the H460 cell line compared to the positive control, KB cells. 
This is unfortunate, as this cell line wouldn’t apply for testing the verteporfin-folate 
conjugate. This conjugate may prove to be a very effective delivery model in vivo, but in 
cell culture, it may not apply very well, unless the appropriate cell line was selected. The 
KB cell line could be suitable for pilot experiments until an appropriate NSCLC cell line 
is identified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
H460 NSCLC Cultures Have a High Percentage of Stem Cells 
 
Typically, stem cells are resistant to traditional chemotherapeutics, which are 
thought to transport the drugs outside of the cell before they have any effect. Verteporfin 
being hydrophobic, can flux back into the cell even after being transported out. More 
importantly, TEAD-induced signaling supports stem cell maintenance. So, verteporfin 
could potentially thwart a stem cell phenotype, possibly making them less resilient. To 
measure the percentage of stem cells and to test if verteporfin may be more selective for 
stem cells, an ALDEFLUOR assay was piloted, since stem cells express high levels of 
aldehyde dehydrogenase isoform 1A1(ALDH1A1) (23) . The rationale behind this being 
that stem cells are more reliant on the Hippo pathway for survival (24). If this is the case, 
verteporfin could be quite effective at limiting their numbers. The ALDEFLUOR assay, 
combined with Flow Cytometry,  measures ALDH activity within the individual cells, 
which is a reliable marker for stemness (25). The assay was conducted on H460 cells and 
H460 spheroids, the latter being enriched with stem cells since they are resistant to 
anoikis.   
The results of the assays showed that after subtracting the isotype from the 
experiment, the H460 cells have a 5.7% ALDH-positive stem population while the H460 
spheroids have 17.7%. This is a considerable stem population, which could yield good 
results for the concluding experiments. Unfortunately, my work does not include the next 
step in the process, which would be to add verteporfin at varying concentrations and see 
if the stem populations lessen with higher concentrations. The results are shown below. 
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Figure 8-A. H460 NSCLC cultured have a relatively high percentage of stem cells. 
The first run is a control that allows an accurate placement of the gate, which transfers 
over onto the experimental run. H460 cells were shown to have a 5.7% stem population. 
Figure 8-B. H460 NSCLC spheroids have a 17.7% stem cell population.  
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DISCUSSION 
 
Preface 
 
 With the conclusion of the results section, I am going to talk about the future 
avenues that this work could pursue. In my work, it is established that verteporfin affects 
NSCLC cell viability. However, there are many areas left blank that this work can be a 
preamble to. For instance, developing and/or acquiring a mouse model for NSCLC would 
help fortify if verteporfin would be affective in vivo or not. This among other possible 
experiments will be discussed in the future experiments subsection.  
 Prior to going over future experiments, ideas and theories will be deliberated 
about verteporfin and the phenomenon that was seen in my experiments with NSCLC. 
There have been many studies with verteporfin being used as a therapeutic agent to treat 
a variety of mouse models of cancers before and after my work began. Some of these 
studies will be discussed to attempt to form a more complete picture.  
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Ideas and Interpretations  
 In my work with NSCLC it is seen that the TEAD-responsive gene CTGF is 
downregulated and p62 is covalently homo-oligomerized with the treatment of 
verteporfin in vitro. Therefore, verteporfin is likely to have at least 2 potential 
mechanisms of action as supported by the literature: (i) inhibition of YAP/TEAD-induced 
gene expression that is associated with survival and proliferation and (ii) protein 
aggregation resulting in disruption of the processes such as autophagy. One or both of 
these mechanisms is responsible for the affects seen in viability, discerning what 
mechanism is responsible for the decrease in viability was an unfinished aim for my 
study. This unfinished aim is important, however, the key point is that verteporfin 
effectively reduces/kills tumors and is not toxic to normal tissues. Studies by others have 
been conducted showing verteporfin’s efficacy in reducing tumor size while not being 
cytotoxic to normal tissue in vivo (9,11). The main modality for cell death differs for the 
two studies referenced above. Liu-Chittenden et al reports that verteporfin suppresses 
liver overgrowth and the formation of hepatocellular carcinoma though the perturbation 
of the YAP-TEAD interaction. While Zhang et al reports that YAP-TEAD has nothing to 
do with reducing colon cancer size or proliferation and that the effects are strictly through 
proteotoxic means. This difference in mechanism is very interesting. It may mean that 
verteporfin might promote apoptosis through different means, depending on what the 
cancers weak points are. As long as there are no deleterious effects on normal tissue; 
which the two studies above show very little toxicity in normal tissue, verteporfin could 
be a great drug for metastatic cancers. The duality of blocking the YAP-TEAD 
interaction and promoting protein crosslinking through its singlet oxygen production are 
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very powerful modes of limiting proliferation, particularly if the crosslinking inhibits 
autophagy.  
 Blocking the YAP-TEAD interaction leads to a decrease in transcription in genes 
associated with proliferation, survival, and stemness. In other words, blocking the YAP-
TEAD interaction decreases proliferation and sensitizes cells to apoptosis while 
decreasing a stem-like nature. These qualities likely make verteporfin synergistic with 
other compounds. Appropriate drugs to combine with verteporfin may be cisplatin or 
erlotinib. Clonogenic and MTT pilot assays were conducted with cisplatin as a candidate 
for synergism, used during, before and after verteporfin treatment. There were no 
discernable differences between the effectiveness of the combination. However, these 
experiments were done while verteporfin was beginning to lose its potency in my assays, 
so the results were not conclusive and not included herein. However, studies by others in 
the lab indicated that verteporfin cooperates with erlotinib in a mutant EGF receptor 
NSCLC cell line, HCC4006, to promote cell death. In addition, after all my experiments 
were concluded, a study reported that ablating YAP1 improves sensitivities to other 
modes of treatment in NSCLC (26). This fortifies the thinking that verteporfin would be 
effective at synergistic treatments and should be further studied.  Since the maximal 
effects of verteporfin on inhibiting cell survival and CTGF expression occurred at lower 
doses than the induction of p62 oligomerization, it is possible that cell death in my hands 
was more dependent on YAP-TEAD signaling.  
Many other proteins other than p62 are more likely than not crosslinked during 
treatment with verteporfin; ones that have been confirmed are STAT3 and lamins (11). 
Also, PCNA maybe crosslinked during treatment, since a study has reported that it is 
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crosslinked with the introduction of singlet oxygen causing agents (27). If the cells have 
normal autophagic and/or proteosomal activity these may be able to be dealt with. Cells 
under stressors, such as tumor cells, may be unable to deal with the added burden of 
compromised proteins building up in the cytosol. Of the proteins that are known to 
crosslink, it is known that the functioning of autophagy and mitosis may be compromised 
(10,27).  This is what I believe to be the most likely cause of the decrease in viability. 
While YAP-TEAD genes are down-regulated during verteporfin treatment, creating a 
higher propensity to become apoptotic, non-functional protein oligomers build up 
ultimately leading to the cell’s failure. Zhang et al came to this conclusion in his studies 
with the use of verteporfin in the treatment of pancreatic cancers (11). I believe the same 
to be true for NSCLC.  Further study is needed in different tumor types to get a more 
definitive answer.  
The following is an experiment that I did not include within the results sections 
because of the inconsistency of the results. The inconsistencies of the results were 
assumed to be from verteporfin having degraded in the stock solution. However, after 
using fresh verteporfin the results were still inconsistent, which leads me to believe there 
were issues elsewhere. It was noted that FBS lots were changed around the month results 
became erratic, but unfortunately, the problem was never resolved.  
Several RT-PCR’s were ran with the H460 cells being exposed to histidine and 
verteporfin at the same time. In the experiment shown below, in figure 9, verteporfin is 
proficient in down regulating CTGF in the presence of 25 mM of histidine. This suggests 
that verteporfin is not acting through singlet oxygen as far as down regulating TEAD-
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responsive genes. This experiment would have to be repeated several times to get a 
conclusive answer though.  
 
 
 
 
Figure 9. CTGF decreases with the addition of verteporfin, even with singlet 
oxygens squelched with histidine.  
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Future Experiments 
There are several hypotheses to investigate in order to build upon and validate the 
results that were generated in the course of my studies. The first hypothesis that should be 
looked into is testing if antioxidant treatment negates verteporfins deleterious effects on 
NSCLC viability. To accomplish this, an MTT and clonogenic assay should be repeated 
using histidine in conjunction with verteporfin. The results would help distinguish if 
verteporfin is acting on viability through the hippo pathway or from protein crosslinkage.  
Secondly, verteporfin may be more effective in limiting stem cell populations than other 
therapies. To see if this would be a viable pursuit, NSCLC stem cells should be exposed 
to verteporfin followed by conducting the ALDEFLUOR assay. In doing so, it can be 
seen if verteporfin affects the population of cells expressing ALDH1A1 (stem-like cells).  
Also, going back into the folate-conjugate can be looked into in the H460 cells. By 
competing the folate-verteporfin conjugates intake with folate, deciphering whether the 
folate-verteporfin conjugate is effective might be plausible. Lastly, verteporfin may be 
more effective in vivo than in vitro. To study this, mouse models would need to be 
developed. It would be costly and time consuming, but the results should yield definitive 
data on whether verteporfin would be effective or not in vivo for NSCLC. 
   The MTT and the clonogenic assay should be repeated with histidine present, as a 
singlet oxygen squelcher, during verteporfin exposure. In doing so, it could be 
determined which modality of verteporfin is responsible for the decrease seen in viability. 
If the cells are more sensitive to verteporfin treatment without histidine, then protein 
crosslinking would be suggested to play a bigger role in cell death. On the other hand, if 
there were no changes in sensitivity, it would be suggested that viability is effected 
40 
strictly from the Hippo pathway. While further study would be needed to say 
convincingly which is the actual culprit, this experiment would be a good indicator at 
which is responsible in NSCLC.  
Another avenue to be looked at is how stem cells are affected with treatment of 
verteporfin. To accomplish this, the ALDEFLUOR assay would be conducted after 
verteporfin treatment for two days. Based on the relative percentage of stem cells 
between the untreated versus the treated cells, it could be deduced how much of an 
impact verteporfin is having on NSCLC stem cells. If verteporfin is effective at limiting 
stem cell survival, it could potentially be used in conjunction with other therapies against 
particularly resistant cancers. Stem cells are typically resistant to traditional 
chemotherapeutics, so having a drug that could target stem cells could be very beneficial.  
After finding out that the relative amount of folate receptors on the H460 cell line 
was very low, furthering study wasn’t conducted. However, it may be possible to use the 
H460 cell line even though there aren’t many receptors. Three separate conditions can be 
set in cell culture; Having cells exposed to the folate-verteporfin conjugate, the other 
being exposed to the folate-verteporfin conjugate + folate to compete, and a control plate. 
These conditions would show if the conjugate is effective at delivering specifically 
through the folate receptor. The results of this experiment would help show if the folate-
verteporfin conjugate should be further looked in to. 
  Lastly, developing a mouse model to test if verteporfin will be effective in vivo 
for NSCLC is paramount if this drug is to go further into clinical trials. SCID mice would 
be used in this experiment, being injected with human lung adenocarcinoma cells 
gathered from patient biopsies. Treatment regimens would begin two weeks after 
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injection. The mice would be treated in sets of three, the regimen being solvent only, 
verteporfin, and the folate-verteporfin conjugate since the latter may be more soluble if 
not more effectively taken up by NSCLC cells.  If tumors shrink while having no 
discernable effect on normal tissues for the verteporfin treatments, verteporfin would 
hold much more weight as being a viable treatment option for NSCLC. 
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